The Regulatory Scheme

All of our studies with MMO thus far indicate that the regulatory scheme [5] differs from that described for P450 m [14]. In particular, there seems to be no effect of methane and most other substrates on the kinetics of formation of any of the intermediates in the reaction cycle prior to Q [60]. On the other hand, the decay rate of Q depends linearly on the concentration of substrate and leads to product formation, so it is likely that substrate enters the reaction cycle at this stage. This is supported by our recent observation that electron transfer from the reduced MMOR to MMOH occurs readily in the absence of substrate at rates that are not rate limiting for the overall reaction (X.-Y. Zhang and J. D. Lipscomb, unpublished observations). Despite the apparent lack of substrate gating in the MMO catalysis, the reconstituted enzyme system is nearly 100% efiScient in methane turnover. This appears to be due to the effects of component complex formation on the rates of specific steps in the cycle and on the redox potentials of the components [25-27, 60]. 

Many plant proteins are of limited nutritional value because of their low content of methionine, which is one of the first essential amino acids to become inadequate in the human diet (Allaway and Thompson, 1966). In spite of the uncertainties of the regulatory scheme shown in Fig. 6, it should provide a useful working model for a rational approach to increasing the methionine content of plants. For example, if the scheme is correct, an overproduction of methionine should result from inhibition of the conversion of methionine to AdoMet, and/or from reducing the allosteric stimulation of... 

Interest has been expressed in the possibility of using biomarker assays as a part of risk assessment for regulatory purposes, and some workers have suggested tiered testing procedures that follow this approach (see, for example, Handy et al. 2003). It is to be hoped that regulatory schemes, such as that of REACH (see European Union 2003), will be sufficiently flexible to incorporate new assays and testing strategies as the science advances. 

Fig. 2.2 Simplified scheme of oxidant/antioxidant regulation ofNF-KB activation. Different stimuli, leading to an increase of ROS generation inside the ceU, activate the phosphorylation of IkB inhibitory protein and the subsequent proteolysis. Thioredoxin (Trx) may reduce activated NF-kB proteins facilitating nuclear translocation.Qnce released from IkB, the NF-kB complex translocates into the nucleus and the binding to DNA domain in the promoters and enhancers of genes such as TNF-a, IL-1, proliferation and chemotactic factors, adhesion molecule. Some of these genes, in turn, may further induce NF-kB activation, leading to a vicious circle if the regulatory cellular system escapes from...

In Australia, approval of clinical trials involves both the regulatory authority and an ethics committee. Under the Clinical Trial Exemption (CTX) scheme, a clinical trial proposal must first be evaluated by the TGA, and then approved by an ethics committee on-site. Under the Clinical Trial Notification (CTN) scheme, a trial is evaluated and approved by the local ethics committee, and then notified to the TGA. 

The REACH scheme has been controversial, with many suggested changes and improvements, but it now seems certain that it will come into force the best estimate is sometime in 2007 (63,118). Industry has been concerned about the practicalities of the scheme, for example it will often be difficult to find out the necessary but commercially sensitive details of downstream use. Industry is also concerned about the costs of compliance, not only for testing, but also in-house management and administration and scientific and regulatory advice and consultancy. Nevertheless, some of the earlier impact assessments probably over-estimated the costs, because... 

There is an EU scheme for classification and labelling of dangerous preparations (i.e., formulations of substances) the Dangerous Preparations Directive (DPD) (a. 7). The EU supplier has to keep a record of the evaluation for inspection by the regulatory authorities. There is no obligation to conduct new studies, but the available information has to be used and interpreted according to the DSD and DPD. 

It is mentioned that the TTC concept has been incorporated in the risk assessment processes in a number of regulatory schemes as a scientifically sound tool to justify waiving or generation of animal data. It is also stressed that, in contrast to approaches such as read-across or chemical categorization, the use of the TTC is not focused or limited to the identification of potential hazards but also provides a quantitative estimate of potency. 

In view of the regulatory delay that was caused by the need to apply for a CTC, a Statutory Order (SI 1974/498) was made during 1974, to provide an exemption from the need to hold a CTC in such cases, subject to certain conditions. This order applied to trials conducted by doctors and dentists on their own responsibility (DDX). The basis of the clinical trial exemption (CTX) scheme, introduced in 1981, to include studies initiated by the pharmaceutical industry, was that together with a detailed clinical trial protocol and summaries of chemical, pharmaceutical, pharmacological, pharmacokinetic, toxicological and human volunteer studies, a clinical trial in patients may proceed without the need for the additional details normally required for a CTC or Product Licence application. This exemption scheme was based on the requirements that ... 

This introduction of the CTX scheme is widely cited as an example of the benefits of deregulation. Australian drug regulatory authorities subsequently also introduced a similar scheme. 

Pressure increased for the TGA to free up the regulatory system for prescription medicines, in particular, the 1990 report by the Australian National Coimcil on AIDS Working Party on the Availability of HIV /AIDS Treatments recommended that a notification scheme be introduced for clinical trials of unapproved products that had already been approved by respected agencies overseas. 

The biosynthesis and secretion of a hormone is regulated by a number of mechanisms and they themselves are involved in complex regulatory schemes. An informative example is the hierarchically ordered hypothalamus-hypophysis system which regulates the biosynthesis and secretion of many hormones of the nuclear receptors. 

---